Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.2340
+0.0140 (6.36%)
May 29, 2025, 11:53 AM HKT
-44.29%
Market Cap 285.35M
Revenue (ttm) 40.88M
Net Income (ttm) -961.40M
Shares Out 1.30B
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 159,500
Average Volume 1,132,153
Open 0.2200
Previous Close 0.2200
Day's Range 0.2200 - 0.2460
52-Week Range 0.1850 - 0.5800
Beta 3.53
RSI 48.92
Earnings Date May 27, 2025

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 300
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2197
Full Company Profile

Financial Performance

In 2024, Clover Biopharmaceuticals's revenue was 38.42 million, a decrease of -2.13% compared to the previous year's 39.26 million. Losses were -903.43 million, 552.1% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.